Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

3,927

Gain on investments in equity

securities, net(5,6) 9,153 143 9,928 12,931

Other 19 (278) (141) (803)

Investment income 13,352 17,246 28,222 33,465

Interest expense (1,149) (3,621) (2,804) (7,809)

Total other income (expenses) 21,938 19,450 36,419 53,268

Income before income taxes(1) 107,971 147,884 313,359 377,264

Provision for income taxes(1) (38,407) (64,090) (98,524) (135,283)

Net income(1) $69,564 $83,794 $214,835 $241,981

Net income per share:

Basic $0.26 $0.32 $0.80 $0.92

Diluted(1,7) $0.25 $0.31 $0.77 $0.88

Weighted average shares

outstanding:

Basic 266,904 263,911 267,127 263,693

Diluted(1,7) 284,262 280,564 285,028 280,244

(1) In accordance with the provisions of Financial Accounting Standards

Board, or FASB, Statement of Financial Accounting Standards No., or

FAS, 123R, "Share-Based Payment, an amendment of FASB Statement Nos.

123 and 95," we recorded pre-tax charges for stock-based compensation

expense and related tax benefits of:

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Cost of products and

services sold $(6,311) $(6,865) $(12,825) $(12,761)

Selling, general and

administrative expense (31,904) (35,248) (54,793) (57,747)

Research and development

expense (16,092) (19,143
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... 5 GenVec, Inc. (Nasdaq:... the third quarter ended September 30, 2009. GenVe...hare) for the three months ended September 30, 200...r share) in the comparable quarter of 2008. For th...et loss was $14.1 million ($0.15 per share), compa...
(Date:11/5/2009)... Nov. 5 ThermoGenesis Co...tive products for processing and storing adult ste...ter of fiscal 2010. ,, For the quarter ended Se... $5.2 million, a 15 percent increase over revenues...The Company said the key contributors to the growt...
(Date:11/5/2009)... 5 Cepheid (Nasdaq: CPH...eaking at the following investor conferences, and ... Credit Suisse Healthcare Conferenc...ber, 2009 at 10 a.m. Mountain Time, ...nd, Tuesday, 1 December, 2009 at 1...
(Date:11/5/2009)...PRNewswire/ -- SpineSmith Partners has signed an i... a unique scaffold that mimics the structure of na...veral commercial products by SpineSmith,s Research...the GenOsteo scaffold represents a significant adv...deal environment for the delivery of adult stem ce...
Breaking Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Cepheid to Webcast Upcoming Financial Presentations 2SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2
... it has received $175,000 from the National Instit...ison and the University of Helsinki, Finland, to d...essence Biosciences Inc. in Madison, will be worki...armful interactions between different drugs given ...IH,s Roadmap for Medical Research program. Keck UW...
Modine Manufacturing earnings drop
...chnology out there than ever before and according...iety, choosing the right combination of the two wi...g has to change and take new roads because theres ...ndless amount of ads, e-mails and spam, faxes, sea...rs attention. All these technology tools are contr...
Other Biology Technology:Exec focuses on blogs as business tool 2
(Date:11/4/2009)...CARLSBAD, Calif., Nov. 4 GenVault ...lliam Brody, M.D., Ph.D., has joined its Board of ...al Chair of the Salk Institute, is an acclaimed ph... joining the Salk Institute, Dr. Brody served as p... member of the National Academy of Engineering and...
(Date:11/3/2009)...LLEIDA, SPAINIn a research report published in a r... Iglesias and Sim Alegre examined the effects of c...uit color, fruit quality, canopy light distributio...eriments were performed using Extenday and Solarma...st in orchards of ,Mondial Gala, apples. The resea...
(Date:11/3/2009)...FORT COLLINS, COConsumer interest in new and diver...rs including the growth of the "local foods" movem...ports touting its numerous health benefits, demand...ing throughout the U.S. , While most grocery sto... (which is most often imported), varieties of "har...
Breaking Biology News(10 mins):Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Reflective film can boost profits for apple growers 2Sustainably grown garlic 2Sustainably grown garlic 3New Study of House Health Reform Bill 3A Kansas Faces Over 24373 Million in Medicare Funded Nursing Home Cuts Over Ten Years 55031 1New Study of House Health Reform Bill 3A Kansas Faces Over 24373 Million in Medicare Funded Nursing Home Cuts Over Ten Years 55031 2New treatments offer better survival and fresh challenges in colorectal cancer 55026 1New treatments offer better survival and fresh challenges in colorectal cancer 55026 2New treatments offer better survival and fresh challenges in colorectal cancer 55026 3PCAST Members Advise President on Future of Healthcare Energy 55024 1PCAST Members Advise President on Future of Healthcare Energy 55024 2
...chnology for a 90 percent reduction of carbon diox...ng developed by a chemical engineer and his collea...of the TXU Carbon Management Program. , TXU Power...ion to the university in support of Chemical Engin...he donation will cover a six-year program to impro...
...r stress or injured, the adrenal gland releases co...mal. But the hormone,s effects are many and varied...ing create memories with short-term exposure, whil...ong. Given the variety of its effects,understandin...edications that can alter its production. , Scient...
...as emerged as a promising alternative for the reco...circumventing the complications associated with tr... repair or regenerate damaged tissue by using engi...nality during regeneration and eventually integrat...ineering paradigm combines isolated cells with app...
Other Biology News:Lower carbon dioxide emissions from coal-fueled power plants possible with technology development 2Lower carbon dioxide emissions from coal-fueled power plants possible with technology development 3Scientists unravel clue in cortisol production 2
... identified as the cellular homolog of the avian s...been shown to be almost identical to c-Jun in thei...zation and DNA binding, whereas their N-terminal d...vation, diverge. Antigen: The antibody was pro...
Mouse Anti-Yersinia pestis Capsular F1 Antigen Monoclonal Antibody, Unconjugated, Clone YBF19 from QED Bioscience Inc.
Rabbit Anti-JMJD2D Polyclonal Antibody, Unconjugated from Abcam
Perm/Wash Buffer from BD Biosciences Pharmingen
Biology Products: